Pfizer and Flynn Pharma are under investigation amid claims they charged “excessive and unfair” prices for a widely-used epilepsy drug in the UK.
The probe by the Competition and Markets Authority is focusing on phenytoin sodium, a drug that has been used to treat epilepsy for decades, which is manufactured by Pfizer but sold in the UK by Flynn Pharma.
It is estimated that around 50,000 people in the UK take phenytoin to control tonic-clonic and focal seizures caused by epilepsy as well as those caused by head trauma or brain surgery.
Pfizer’s brand name for the drug in the UK was Epanutin and according to the CMA the NHS spent around £2.3m on the drug before it sold the UK distribution rights to Flynn Pharma in 2012, which promptly de-branded the product.
Full content: Mail Online
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI